These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 33478708)

  • 1. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
    Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
    Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
    Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
    J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
    Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
    J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
    Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY
    JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
    Bakhshaliyev N; Özdemir R
    Ann Noninvasive Electrocardiol; 2021 Jul; 26(4):e12846. PubMed ID: 33956361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
    Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
    J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
    Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
    Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
    Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
    Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
    Million M; Lagier JC; Hourdain J; Franceschi F; Deharo JC; Parola P; Brouqui P
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241095
    [No Abstract]   [Full Text] [Related]  

  • 14. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
    J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
    Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L
    Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
    Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
    Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.